Loading Events

« All Events

  • This event has passed.

Special Webinar: NICE Guidance explained

June 29, 2024 @ 11:00 am - 12:00 pm

Burosumab is a relatively new treatment, which has been fully approved as an effective treatment for both children and adults. It is the only treatment that deals with the root cause of X-linked hypophosphataemia.

In people with XLH, the hormone fibroblast growth factor 23 (FGF23) is overactive, which signals to decrease the phosphate in the blood, resulting in poor bone mineralisation. Burosumab (marketed as Crysvita) is a monoclonal antibody that suppresses the activity of fibroblast growth factor 23 (FGF23). By suppressing FGF23, burosumab normalises the phosphate levels in the blood, which helps bones and teeth to form properly.

Implementation of NHS guidelines to make burosumab available to all UK adults is in the process of being rolled out – find out more by clicking here.

Details

Date:
June 29, 2024
Time:
11:00 am - 12:00 pm
Event Categories:
,

Venue

Zoom (online meeting)

Organizer

XLH UK
Email
contact@xlhuk.org